Circulation. 2004;110:227-239
doi: 10.1161/01.CIR.0000133317.49796.0E
doi: 10.1161/01.CIR.0000133317.49796.0E
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2004;110:227-239.)
© 2004 American Heart Association, Inc.
NCEP Report |
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Abstract
The Adult Treatment Panel III (ATP III) of the National Cholesterol Education Program issued an evidence-based set of guidelines on cholesterol management in 2001. Since the publication of ATP III, 5 major clinical trials of statin therapy with clinical end points have been published. These trials addressed issues that were not examined in previous clinical trials of cholesterol-lowering therapy. The present document reviews the results of these recent trials and assesses their implications for cholesterol management. Therapeutic lifestyle changes (TLC) remain an essential modality in clinical management. The trials confirm the benefit of cholesterol-lowering therapy in high-risk patients and support the ATP III treatment goal of low-density lipoprotein cholesterol (LDL-C) <100 mg/dL. They support the inclusion of patients with diabetes in the high-risk category and confirm the benefits of LDL-lowering therapy in these patients. They further confirm that older persons benefit from therapeutic lowering of LDL-C. The major recommendations for modifications to footnote the ATP III treatment algorithm are the following. In high-risk persons, the recommended LDL-C goal is <100 mg/dL, but when risk is very high, an LDL-C goal of <70 mg/dL is a therapeutic option, ie, a reasonable clinical strategy, on the basis of available clinical trial evidence. This therapeutic option extends also to patients at very high risk who have a baseline LDL-C <100 mg/dL. Moreover, when a high-risk patient has high triglycerides or low high-density lipoprotein cholesterol (HDL-C), consideration can be given to combining a fibrate or nicotinic acid with an LDL-lowering drug. For moderately high-risk persons (2+ risk factors and 10-year risk 10% to 20%), the recommended LDL-C goal is <130 mg/dL, but an LDL-C goal <100 mg/dL is a therapeutic option on the basis of recent trial evidence. The latter option extends also to moderately high-risk persons with a baseline LDL-C of 100 to 129 mg/dL. When LDL-lowering drug therapy is employed in high-risk or moderately high-risk persons, it is advised that intensity of therapy be sufficient to achieve at least a 30% to 40% reduction in LDL-C levels. Moreover, any person at high risk or moderately high risk who has lifestyle-related risk factors (eg, obesity, physical inactivity, elevated triglycerides, low HDL-C, or metabolic syndrome) is a candidate for TLC to modify these risk factors regardless of LDL-C level. Finally, for people in lower-risk categories, recent clinical trials do not modify the goals and cutpoints of therapy.
Key Words: cholesterol • trials • lipoproteins • coronary disease
This article has been cited by other articles:
 |
|
 |
|
  D J Hausenloy and D M Yellon Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels Heart, June 1, 2008; 94(6): 706 - 714. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. D. Schocken, E. J. Benjamin, G. C. Fonarow, H. M. Krumholz, D. Levy, G. A. Mensah, J. Narula, E. S. Shor, J. B. Young, and Y. Hong Prevention of Heart Failure: A Scientific Statement From the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group Circulation, May 13, 2008; 117(19): 2544 - 2565. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. P. Glasziou, L. Irwig, S. Heritier, R. J. Simes, A. Tonkin, and for the LIPID Study Investigators Monitoring Cholesterol Levels: Measurement Error or True Change? Ann Intern Med, May 6, 2008; 148(9): 656 - 661. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Kolloch, U. F. Legler, A. Champion, R. M. Cooper-DeHoff, E. Handberg, Q. Zhou, and C. J. Pepine Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST) Eur. Heart J., May 2, 2008; 29(10): 1327 - 1334. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. Eckel Nonsurgical Management of Obesity in Adults N. Engl. J. Med., May 1, 2008; 358(18): 1941 - 1950. [Full Text] [PDF]
|
|
|
|
 |
|
 R. A Dale, L. H Jensen, and M. J Krantz Comparison of Two Point-of-Care Lipid Analyzers for Use in Global Cardiovascular Risk Assessments Ann. Pharmacother., May 1, 2008; 42(5): 633 - 639. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. K. Wenger Current Status of Cardiac Rehabilitation J. Am. Coll. Cardiol., April 29, 2008; 51(17): 1619 - 1631. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Jackevicius, J. V. Tu, J. S. Ross, D. T. Ko, and H. M. Krumholz Use of Ezetimibe in the United States and Canada N. Engl. J. Med., April 24, 2008; 358(17): 1819 - 1828. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Guyton, B. G. Brown, S. Fazio, A. Polis, J. E. Tomassini, and A. M. Tershakovec Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia. J. Am. Coll. Cardiol., April 22, 2008; 51(16): 1564 - 1572. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Shepherd, J. J.P. Kastelein, V. Bittner, P. Deedwania, A. Breazna, S. Dobson, D. J. Wilson, A. Zuckerman, N. K. Wenger, and for the TNT (Treating to New Targets) Investigator Intensive Lipid Lowering With Atorvastatin in Patients With Coronary Heart Disease and Chronic Kidney Disease: The TNT (Treating to New Targets) Study J. Am. Coll. Cardiol., April 15, 2008; 51(15): 1448 - 1454. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. K. Schramm, G. H. Gislason, L. Kober, S. Rasmussen, J. N. Rasmussen, S. Z. Abildstrom, M. L. Hansen, F. Folke, P. Buch, M. Madsen, et al. Diabetes Patients Requiring Glucose-Lowering Therapy and Nondiabetics With a Prior Myocardial Infarction Carry the Same Cardiovascular Risk: A Population Study of 3.3 Million People Circulation, April 15, 2008; 117(15): 1945 - 1954. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. V. Howard, M. J. Roman, R. B. Devereux, J. L. Fleg, J. M. Galloway, J. A. Henderson, Wm. J. Howard, E. T. Lee, M. Mete, B. Poolaw, et al. Effect of Lower Targets for Blood Pressure and LDL Cholesterol on Atherosclerosis in Diabetes: The SANDS Randomized Trial JAMA, April 9, 2008; 299(14): 1678 - 1689. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C.E. Rossi, A. Nicolucci, F. Pellegrini, M. Comaschi, A. Ceriello, D. Cucinotta, C. Giorda, U. Valentini, G. Vespasiani, and S. De Cosmo Identifying patients with type 2 diabetes at high risk of microalbuminuria: results of the DEMAND (Developing Education on Microalbuminuria for Awareness of reNal and cardiovascular risk in Diabetes) Study Nephrol. Dial. Transplant., April 1, 2008; 23(4): 1278 - 1284. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N K Wenger, S J Lewis, F K Welty, D M Herrington, V Bittner, and on behalf of the TNT Steering Committee and Invest Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study Heart, April 1, 2008; 94(4): 434 - 439. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Krauss, L. M. Mangravite, J. D. Smith, M. W. Medina, D. Wang, X. Guo, M. J. Rieder, J. A. Simon, S. B. Hulley, D. Waters, et al. Variation in the 3-Hydroxyl-3-Methylglutaryl Coenzyme A Reductase Gene Is Associated With Racial Differences in Low-Density Lipoprotein Cholesterol Response to Simvastatin Treatment Circulation, March 25, 2008; 117(12): 1537 - 1544. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Y. Bang, J. L. Saver, D. S. Liebeskind, S. Pineda, and B. Ovbiagele Association of serum lipid indices with large artery atherosclerotic stroke Neurology, March 11, 2008; 70(11): 841 - 847. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Gottlieb and J. A.C. Lima Screening High-Risk Patients With Computed Tomography Angiography Circulation, March 11, 2008; 117(10): 1318 - 1332. [Full Text] [PDF]
|
|
|
|
|
|
H. C. McGill Jr, C. A. McMahan, and S. S. Gidding Preventing Heart Disease in the 21st Century: Implications of the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Study Circulation, March 4, 2008; 117(9): 1216 - 1227. [Full Text] [PDF]
|
|
|
|
|
|
F.L.J. Visseren Vascular consequences of metabolic syndrome in early life Eur. Heart J., March 2, 2008; 29(6): 693 - 694. [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Shirali and M. J. Bia Management of Cardiovascular Disease in Renal Transplant Recipients Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(2): 491 - 504. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M Backes, C. V Venero, C. A Gibson, J. F Ruisinger, P. A Howard, P. D Thompson, and P. M Moriarty Effectiveness and Tolerability of Every-Other-Day Rosuvastatin Dosing in Patients with Prior Statin Intolerance Ann. Pharmacother., March 1, 2008; 42(3): 341 - 346. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Grundy A changing paradigm for prevention of cardiovascular disease: emergence of the metabolic syndrome as a multiplex risk factor Eur. Heart J. Suppl., March 1, 2008; 10(suppl_B): B16 - B23. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Josan MD, S. R. Majumdar MD MPH, and F. A. McAlister MD MSc The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials Can. Med. Assoc. J., February 26, 2008; 178(5): 576 - 584. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J L Bell, L. Irwig, J. C Craig, and P. Macaskill Use of randomised trials to decide when to monitor response to new treatment BMJ, February 16, 2008; 336(7640): 361 - 365. [Full Text] [PDF]
|
|
|
|
|
|
J. Genest The Yin and Yang of high-density lipoprotein cholesterol. J. Am. Coll. Cardiol., February 12, 2008; 51(6): 643 - 644. [Full Text] [PDF]
|
|
|
|
|
|
H. Holdaas Statin therapy for prevention of coronary artery disease. The earlier the better or the longer the better? Eur. Heart J., February 2, 2008; 29(4): 425 - 426. [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Andon and J. W. Anderson State of the Art Reviews: The Oatmeal-Cholesterol Connection: 10 Years Later American Journal of Lifestyle Medicine, February 1, 2008; 2(1): 51 - 57. [Abstract] [PDF]
|
|
|
|
 |
|
 C. S. Madsen, E. Janovitz, R. Zhang, Van Nguyen-Tran, C. S. Ryan, X. Yin, H. Monshizadegan, M. Chang, C. D'Arienzo, S. Scheer, et al. The Guinea Pig as a Preclinical Model for Demonstrating the Efficacy and Safety of Statins J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 576 - 586. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. O. Stirban and D. Tschoepe Cardiovascular Complications in Diabetes: Targets and interventions Diabetes Care, February 1, 2008; 31(Supplement_2): S215 - S221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. O. Stirban and D. Tschoepe Should We Be More Aggressive in the Therapy Against Cardiovascular Risk Factors?: Should we prescribe statin and aspirin for every diabetic patient, or is it time for a polypill? Diabetes Care, February 1, 2008; 31(Supplement_2): S226 - S228. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. A. Iakoubova, C. H. Tong, C. M. Rowland, T. G. Kirchgessner, B. A. Young, A. R. Arellano, D. Shiffman, M. S. Sabatine, H. Campos, C. J. Packard, et al. Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J. Am. Coll. Cardiol., January 29, 2008; 51(4): 435 - 443. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Grundy Promise of Low-Density Lipoprotein-Lowering Therapy for Primary and Secondary Prevention Circulation, January 29, 2008; 117(4): 569 - 573. [Full Text] [PDF]
|
|
|
|
|
|
S. E. Inzucchi and D. K. McGuire New Drugs for the Treatment of Diabetes: Part II: Incretin-Based Therapy and Beyond Circulation, January 29, 2008; 117(4): 574 - 584. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Blumenthal, C. N. Bairey Merz, V. Bittner, and T. J. Gluckman Task Force 10: Training in Preventive Cardiovascular Medicine J. Am. Coll. Cardiol., January 22, 2008; 51(3): 393 - 398. [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Grundy Thyroid mimetic as an option for lowering low-density lipoprotein PNAS, January 15, 2008; 105(2): 409 - 410. [Full Text] [PDF]
|
|
|
|
|
|
A. M.J. Wassink, Y. van der Graaf, J. K. Olijhoek, F. L.J. Visseren, and for the SMART Study Group Metabolic syndrome and the risk of new vascular events and all-cause mortality in patients with coronary artery disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm Eur. Heart J., January 2, 2008; 29(2): 213 - 223. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S Lund, L. Tarnow, M. Frandsen, U. M Smidt, O. Pedersen, H.-H. Parving, and A. A Vaag Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes Eur. J. Endocrinol., January 1, 2008; 158(1): 35 - 46. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. deGoma, N. J. Leeper, and P. A. Heidenreich Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol. J. Am. Coll. Cardiol., January 1, 2008; 51(1): 49 - 55. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Peters Clinical Relevance of Non-HDL Cholesterol in Patients With Diabetes Clin. Diabetes, January 1, 2008; 26(1): 3 - 7. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. W. Nesto LDL Cholesterol Lowering in Type 2 Diabetes: What Is the Optimum Approach? Clin. Diabetes, January 1, 2008; 26(1): 8 - 13. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Charlton-Menys and P. N. Durrington Human cholesterol metabolism and therapeutic molecules Exp Physiol, January 1, 2008; 93(1): 27 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kinlay, G. G. Schwartz, A. G. Olsson, N. Rifai, M. Szarek, D. D. Waters, P. Libby, P. Ganz, and for the Myocardial Ischemia Reduction with Aggress Inflammation, Statin Therapy, and Risk of Stroke After an Acute Coronary Syndrome in the MIRACL Study Arterioscler. Thromb. Vasc. Biol., January 1, 2008; 28(1): 142 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
American Diabetes Association Standards of Medical Care in Diabetes--2008 Diabetes Care, January 1, 2008; 31(Supplement_1): S12 - S54. [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Preis and C. J. O'Donnell Coronary Heart Disease Risk Assessment by Traditional Risk Factors and Newer Subclinical Disease Imaging: Is a "One-Size-Fits-All" Approach the Best Option? Arch Intern Med, December 10, 2007; 167(22): 2399 - 2401. [Full Text] [PDF]
|
|
|
|
|
|
T. D. Fraker Jr, S. D. Fihn, and Writing on behalf of the 2002 Chronic Stable Angin 2007 Chronic Angina Focused Update of the ACC/AHA 2002 Guidelines for the Management of Patients With Chronic Stable Angina: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to Develop the Focused Update of the 2002 Guidelines for the Management of Patients With Chronic Stable Angina J. Am. Coll. Cardiol., December 4, 2007; 50(23): 2264 - 2274. [Full Text] [PDF]
|
|
|
|
|
|
T. D. Fraker Jr, S. D. Fihn, Writing on behalf of the 2002 Chronic Stable Angin, 2002 WRITING COMMITTEE MEMBERS, R. J. Gibbons, J. Abrams, K. Chatterjee, J. Daley, P. C. Deedwania, J. S. Douglas, et al. 2007 Chronic Angina Focused Update of the ACC/AHA 2002 Guidelines for the Management of Patients With Chronic Stable Angina: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to Develop the Focused Update of the 2002 Guidelines for the Management of Patients With Chronic Stable Angina Circulation, December 4, 2007; 116(23): 2762 - 2772. [Full Text] [PDF]
|
|
|
|
|
|
C. E. O'Neil and T. A. Nicklas State of the Art Reviews: Relationship Between Diet/ Physical Activity and Health American Journal of Lifestyle Medicine, December 1, 2007; 1(6): 457 - 481. [Abstract] [PDF]
|
|
|
|
|
|
R. Erbel, S. Mohlenkamp, G. Kerkhoff, T. Budde, and A. Schmermund Non-invasive screening for coronary artery disease: calcium scoring Heart, December 1, 2007; 93(12): 1620 - 1629. [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Preston, P. Harvey, O. Herfert, G. Dykstra, J. W. Jukema, F. Sun, and D. Gillen A Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacodynamic Interaction of Coadministered Amlodipine and Atorvastatin in 1660 Patients With Concomitant Hypertension and Dyslipidemia: The Respond Trial J. Clin. Pharmacol., December 1, 2007; 47(12): 1555 - 1569. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Amarenco, L. B. Goldstein, M. Szarek, H. Sillesen, A. E. Rudolph, A. Callahan III, M. Hennerici, L. Simunovic, J. A. Zivin, K. M. A. Welch, et al. Effects of Intense Low-Density Lipoprotein Cholesterol Reduction in Patients With Stroke or Transient Ischemic Attack: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial Stroke, December 1, 2007; 38(12): 3198 - 3204. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. N Henyan, D. M Riche, H. E East, and P. N Gann Impact of Statins on Risk of Stroke: A Meta-Analysis Ann. Pharmacother., December 1, 2007; 41(12): 1937 - 1945. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Chaturvedi, T. N. Turan, M. J. Lynn, S. E. Kasner, J. Romano, G. Cotsonis, M. Frankel, M. I. Chimowitz, and For the WASID Study Group Risk factor status and vascular events in patients with symptomatic intracranial stenosis Neurology, November 27, 2007; 69(22): 2063 - 2068. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Bodenheimer A 63-Year-Old Man With Multiple Cardiovascular Risk Factors and Poor Adherence to Treatment Plans JAMA, November 7, 2007; 298(17): 2048 - 2055. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Arredondo, D. Jorquera, E. Carrasco, C. Albala, and E. Hertrampf Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with iron status in persons with type 2 diabetes mellitus Am. J. Clinical Nutrition, November 1, 2007; 86(5): 1347 - 1353. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Devaraj, R. Tang, B. Adams-Huet, A. Harris, T. Seenivasan, J. A de Lemos, and I. Jialal Effect of high-dose {alpha}-tocopherol supplementation on biomarkers of oxidative stress and inflammation and carotid atherosclerosis in patients with coronary artery disease Am. J. Clinical Nutrition, November 1, 2007; 86(5): 1392 - 1398. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Thielmann, M. Neuhauser, A. Marr, B. R. Jaeger, D. Wendt, B. Schuetze, M. Kamler, P. Massoudy, R. Erbel, and H. Jakob Lipid-lowering effect of preoperative statin therapy on postoperative major adverse cardiac events after coronary artery bypass surgery. J. Thorac. Cardiovasc. Surg., November 1, 2007; 134(5): 1143 - 1149. [Abstract] [Full Text] [PDF]
|
|